Translations:Ipragliflozin/10/en

However, ipragliflozin is currently in Observational Case Control clinical trial to see the long-term (over three years) safety of using ipragliflozin. The estimated completion of this trial is October 2018.

18 October 2016: Astellas completes a clinical trial for Type-2 diabetes mellitus in Japan prior to October 2016
7 September 2016: Astellas Pharma plans a phase III trial for Type-1 diabetes mellitus (Combination therapy) in Japan
1 August 2016: Phase III clinical trials in type 1 diabetes mellitus (combination therapy) in Japan